Carlin Chuck

Carlin Chuck

Auto-generated profile, based on publicly available information

Carlin Chuck

Department of Neurosurgery, Brown University, Providence, Rhode Island

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Injury
Verified
Journal Article
Closed access
CCCarlin C. Chuck
Carlin C. Chuck
TMThomas J. Martin
Thomas J. Martin
RKRoshini Kalagara
Roshini Kalagara
ESElias Shaaya
Elias Shaaya
TKTareq Kheirbek
Tareq Kheirbek
DCDeus Cielo
Deus Cielo

29 January 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Mazen TamanMazen Taman
Mazen Taman
HAHael Abdulrazeq
Hael Abdulrazeq
CCCarlin Chuck
Carlin Chuck
RSRahul A. Sastry
Rahul A. Sastry
RARohaid Ali
Rohaid Ali
JFJared Fridley
Jared Fridley
Acute spinal cord injury (SCI) often results in severe neurologic deficits, with hemodynamic instability contributing to secondary ischemic damage. Beyond surgical decompression, maintaining adequate mean arterial pressure (MAP) is key to enhancing spinal cord perfusion and oxygenation. Vasopressor therapy is frequently used to achieve hemodynamic stability, but optimal MAP targets and vasopressor selection remain controversial. This review explores updated guidelines and current evidence regarding MAP management and the use of vasopressors in SCI, focusing on their impact on spinal cord perfusion and neurologic outcomes. Recent studies highlight the role of durotomy in directly improving spinal cord perfusion pressure (SCPP) by reducing intraspinal pressure (ISP), offering a complementary mechanical intervention as part of pharmacologic therapies. Recent guidelines suggest an MAP range of 75–80 mmHg as a lower limit and 90–95 mmHg as an upper limit for 3–7 days post-injury, highlighting the need for personalized hemodynamic management. Norepinephrine is commonly preferred due to its balanced effects on peripheral vascular resistance and spinal cord perfusion pressure (SCPP), though dopamine, phenylephrine, and dobutamine each offer unique hemodynamic profiles suited to specific clinical scenarios. Despite their benefits, vasopressors carry significant risks, including arrhythmias and potential myocardial strain, necessitating careful selection based on individual patient factors. Further research is needed to refine vasopressor use and establish evidence-based protocols that optimize neurologic recovery, alongside continued exploration of SCPP as a potential therapeutic target.

1 December 2021 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
SDSavannah R. Doelfel
Savannah R. Doelfel
RKRoshini Kalagara
Roshini Kalagara
EHEthan J. Han
Ethan J. Han
CCCarlin C. Chuck
Carlin C. Chuck
HDHari Dandapani
Hari Dandapani
MRMichael Reznik
Michael Reznik

23 September 2021 in Neurology
Verified
Journal Article
Closed access
PDF file
CCCarlin C. Chuck
Carlin C. Chuck
DKDaniel Kim
Daniel Kim
RKRoshini Kalagara
Roshini Kalagara
NRNathaniel Rex
Nathaniel Rex
TMTracy E. Madsen
Tracy E. Madsen
MRMichael Reznik
Michael Reznik
Background and Objectives Andexanet alfa was recently approved as a reversal agent for the factor Xa inhibitors (FXais) apixaban and rivaroxaban, but its impact on long-term outcomes in FXai-associated intracerebral hemorrhage (ICH) is unknown. We aimed to explore potential clinical implications of andexanet alfa in FXai-associated ICH in this simulation study. Methods We simulated potential downstream implications of andexanet alfa across a range of possible hemostatic effects using data from a single center that treats FXai-associated ICH with prothrombin complex concentrate (PCC). We determined baseline probabilities of inadequate hemostasis across patients taking FXai and those not taking FXai via multivariable regression models and then determined the probabilities of unfavorable 3-month outcome (modified Rankin Scale score 4–6) using models comprising established predictors and each patient9s calculated probability of inadequate hemostasis. We applied bootstrapping with model parameters from this derivation cohort to simulate a range of hemostatic improvements and corresponding outcomes and then calculated absolute risk reduction (relative to PCC) and projected number needed to treat (NNT) to prevent 1 unfavorable outcome. Results Training models using real-world patients (n = 603 total, 55 on FXai) had good accuracy in predicting inadequate hemostasis (area under the curve [AUC] 0.78) and unfavorable outcome (AUC 0.78). Inadequate hemostasis was strongly associated with unfavorable outcome (odds ratio 4.5, 95% confidence interval [CI] 2.0–9.9) and occurred in 11.4% of patients taking FXai. Across simulated patients taking FXai comparable to those in A Study in Participants With Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors (ANNEXA-4) study, predicted absolute risk reduction of unfavorable outcome was 4.9% (95% CI 1.3%–7.8%) when the probability of inadequate hemostasis was reduced by 33% and 7.4% (95% CI 2.0%–11.9%) at 50% reduction, translating to projected NNT of 21 (cumulative cost $519,750) and 14 ($346,500), respectively. Discussion Even optimistic simulated hemostatic effects suggest that the costs and potential benefits of andexanet alfa should be carefully considered. Placebo-controlled randomized trials are needed before its use can definitively be recommended.

12 May 2022 in Interventional Neuroradiology
Verified
Journal Article
Closed access
JFJoshua Feler
Joshua Feler
CCCarlin Chuck
Carlin Chuck
MAMatthew Anderson
Matthew Anderson
JPJonathan Poggi
Jonathan Poggi
JSJoseph Sweeney
Joseph Sweeney
RTRadmehr Torabi
Radmehr Torabi
Intro: SARS-CoV-2 (COVID-19) infection is associated with acute ischemic stroke (AIS), which may be due to a prothrombotic state. Early reports have suggested high rates of reocclusion following mechanical thrombectomy (MT) with poor radiographic and clinical outcomes. We report our early experience using intra-procedural antithrombotics to address SARS-CoV-2 reocclusion. Methods: We identified 6 patients that experienced early reocclusion after MT for COVID-19-associated AIS through retrospective chart review abstracting their basic demographics, COVID-19 status, and stroke management. All these patients were treated after reocclusion with aspirin and cangrelor intra-procedurally, the latter of which was converted to ticagrelor post-procedurally. Some patients additionally received argatroban infusion intraprocedurally. Results: Mean age was 54. There were 3 post-procedural and 3 intra-procedural re-occlusions. After repeat thrombectomy and treatment with aspirin and cangrelor, those with post-procedure reocclusion did not show further reocclusion, while those with intra-procedural reocclusion showed radiographic improvement with intraprocedural cangrelor administration. Outcomes for these patients were poor, with a median mRS of 4. Two patients developed petechial hemorrhage of their stroke which was managed conservatively, and one developed a retroperitoneal hemorrhage from femoral access requiring transfusion. There were no patients who developed new parenchymal hematomas. Conclusion: COVID-19 AIS may be associated with a hypercoagulable state which risks malignant reocclusion complicating MT. We found antithrombotic treatment periprocedural cangrelor with or without argatroban transitioned to oral aspirin with ticagrelor to be a viable method for management of these patients.

25 August 2025 in Journal of Neurosurgery: Case Lessons
Verified
Journal Article
Open access
EWElaina J. Wang
Elaina J. Wang
GKGiovanni Kozel
Giovanni Kozel
CCCarlin C. Chuck
Carlin C. Chuck
MPMichael Punsoni
Michael Punsoni
PSPatricia L Sullivan
Patricia L Sullivan
BACKGROUND: Multiple myeloma (MM) and plasmacytoma metastases to the spine are extremely rare, with 9 cases reported in the literature. Only 2 describe cases of solitary plasmacytoma (SP) specifically in the cervical spine, both in patients without known histories of MM. Therefore, the natural history of MM recurrence as SP in the cervical spine remains unknown. OBSERVATIONS: The authors describe the case of a 67-year-old woman with a history of MM after stem cell transplant and chemotherapy in remission for a year who presented with progressive cervical myelopathy found to have an intradural extramedullary solitary lesion at C2–3 on MRI of the whole spine. The patient underwent C1–3 laminectomies for decompression and intradural biopsy of the lesion, with pathology consistent with plasmacytoma. The patient’s motor examination improved significantly postoperatively. LESSONS: SP should be included in the differential diagnosis for intradural extramedullary lesions found in the spine, particularly in patients with a history of MM and tumor resistance to radiotherapy. Despite plasmacytoma’s classically radiosensitive nature, it is possible to have residual tumor after radiation therapy. In these cases, patients may benefit greatly from surgical biopsy and decompression followed by adjuvant radiotherapy. https://thejns.org/doi/10.3171/CASE24731